Clinical Trials Browser

Terminated × Breast Neoplasms × Celecoxib × Clear all

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Phase 2 Terminated

3 enrolled 6 charts

Breast Neoplasms

NCT00075673 2020-07-27

Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT00088972 2018-08-10

S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women

Phase 2 Terminated

8 enrolled 5 charts

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Ductal, Breast

NCT00045591 2017-01-11

Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT01067989 2015-07-08

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00101062 2011-06-08

Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms